Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

25, 2025 — In recent years, cell ... treatment and mortality from data on over 500,000 lung cancer patients. This study suggests that immunotherapy may not be the optimal ... New, Rare Type of ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer ... questions about Opdivo for squamous cell lung cancer treatment, talk with your doctor.

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...

Surgery remains the mainstay of treatment for early-stage [non-small cell lung cancer (NSCLC)], regardless of age,” researchers wrote in the Journal of ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...